ATE424192T1 - Stabile pharmazeutische zubereitungen mit 2-aza- bicyclo 3.3.0 -octan-3-carboxylsäure-derivaten - Google Patents

Stabile pharmazeutische zubereitungen mit 2-aza- bicyclo 3.3.0 -octan-3-carboxylsäure-derivaten

Info

Publication number
ATE424192T1
ATE424192T1 AT04756130T AT04756130T ATE424192T1 AT E424192 T1 ATE424192 T1 AT E424192T1 AT 04756130 T AT04756130 T AT 04756130T AT 04756130 T AT04756130 T AT 04756130T AT E424192 T1 ATE424192 T1 AT E424192T1
Authority
AT
Austria
Prior art keywords
aza
bicyclo
octane
carboxylic acid
acid derivatives
Prior art date
Application number
AT04756130T
Other languages
English (en)
Inventor
Julia Hrakovsky
Ruth Tenengauzer
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE424192T1 publication Critical patent/ATE424192T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04756130T 2003-06-26 2004-06-24 Stabile pharmazeutische zubereitungen mit 2-aza- bicyclo 3.3.0 -octan-3-carboxylsäure-derivaten ATE424192T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48251803P 2003-06-26 2003-06-26

Publications (1)

Publication Number Publication Date
ATE424192T1 true ATE424192T1 (de) 2009-03-15

Family

ID=33563864

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04756130T ATE424192T1 (de) 2003-06-26 2004-06-24 Stabile pharmazeutische zubereitungen mit 2-aza- bicyclo 3.3.0 -octan-3-carboxylsäure-derivaten

Country Status (12)

Country Link
US (3) US20050069586A1 (de)
EP (1) EP1635792B1 (de)
AT (1) ATE424192T1 (de)
CA (1) CA2530788C (de)
DE (1) DE602004019777D1 (de)
DK (1) DK1635792T3 (de)
ES (1) ES2322854T3 (de)
IL (1) IL172602A0 (de)
MX (1) MXPA06000226A (de)
PL (1) PL1635792T3 (de)
PT (1) PT1635792E (de)
WO (1) WO2005002548A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2322854T3 (es) * 2003-06-26 2009-06-30 Teva Pharmaceutical Industries Limited Composiciones farmaceuticas estables de derivados del acido 2-aza-biciclo(3.3.0)-octano-3-carboxilico.
US20050095287A1 (en) * 2003-10-29 2005-05-05 Matharu Amol S. Fosinopril composition
US20080234353A1 (en) * 2004-03-24 2008-09-25 Reynir Eyjolfsson Formulations of Ramipril
LT1729739T (lt) * 2004-03-29 2016-11-10 Les Laboratoires Servier Kietos farmacinės kompozicijos gamybos būdas
CA2586760A1 (en) * 2004-11-05 2006-05-18 Edward S. Wilson Stabilized ramipril compositions and methods of making
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
KR20080112387A (ko) * 2006-04-19 2008-12-24 테바 파마슈티컬 인더스트리즈 리미티드 2-아자-비사이클로[3.3.0]-옥탄-3-카르복실산 유도체의 안정한 약학 조성물
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
WO2008132756A1 (en) * 2007-05-01 2008-11-06 Lupin Limited Stable pharmaceutical compositions of ramipril
TR200906322A2 (tr) 2009-08-17 2011-07-21 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite özellikleri geliştirilmiş granüller.
EP2739272A1 (de) * 2011-08-01 2014-06-11 Teva Pharmaceutical Industries Ltd. Verfahren für die zubereitung von pharmazeutischen zusammensetzungen mit fingolimod
CN107441495A (zh) 2012-02-17 2017-12-08 埃吉斯药物私人有限公司 稳定性提高的药物制剂
HUP1300496A2 (hu) 2013-08-16 2015-03-02 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Stabil kombinációs gyógyszerkészítmény
EP3275432A1 (de) * 2016-07-25 2018-01-31 H e x a l Aktiengesellschaft Darreichungsform mit ace-hemmer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2812314A (en) * 1952-08-23 1957-11-05 Monsanto Chemicals Calcium and alkali metal double salts of hydrolyzed polyacrylonitrile
US2812344A (en) * 1956-02-13 1957-11-05 Ortho Pharma Corp Ferrous calcium citrate complex
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
DE3226768A1 (de) * 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
US4793998A (en) * 1986-10-20 1988-12-27 Warner-Lambert Company Stabilized drug compositions
US4830853A (en) * 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4743450A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
DE3739690A1 (de) * 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
US5054483A (en) * 1989-03-06 1991-10-08 Hood Laboratories Tracheal cannulas and stents
US4973470A (en) * 1989-06-26 1990-11-27 Warner-Lambert Company Sustained release pharmaceutical compositions
US5006344A (en) * 1989-07-10 1991-04-09 E. R. Squibb & Sons, Inc. Fosinopril tablet formulations
DK9200258U4 (da) * 1992-03-11 1993-07-23 Merck & Co Inc Farmaceutisk præparat indeholdende enalapril til brug mod hypertension
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
CN1144598C (zh) * 1998-06-05 2004-04-07 沃尼尔·朗伯公司 利用氧化镁稳定的含ace抑制剂的组合物
US6555551B1 (en) * 1999-08-31 2003-04-29 Mutual Pharmaceutical Co., Inc. Stable formulations of ACE inhibitors, and methods for preparation thereof
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
CA2330904C (en) * 2001-01-11 2006-10-24 Bernard Charles Sherman Fosinopril sodium tablet formulation
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
IS1935B (is) * 2002-03-19 2004-06-16 Actavis Group Hf. Fósínópríl lyfjasamsetning
AU2003227691B2 (en) * 2002-05-03 2008-05-15 Hexal Ag Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor
PE20040468A1 (es) * 2002-05-17 2004-09-14 Novartis Ag Combinacion de compuestos organicos
AR039744A1 (es) * 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
ES2322854T3 (es) * 2003-06-26 2009-06-30 Teva Pharmaceutical Industries Limited Composiciones farmaceuticas estables de derivados del acido 2-aza-biciclo(3.3.0)-octano-3-carboxilico.
US6869963B2 (en) * 2003-07-11 2005-03-22 Sandoz Ag Stable pharmaceutical compositions containing an ACE inhibitor
US20050181055A1 (en) * 2003-10-08 2005-08-18 Mathur Rajeev S. Pharmaceutical compositions of quinapril
US20050095287A1 (en) * 2003-10-29 2005-05-05 Matharu Amol S. Fosinopril composition
US20050256056A1 (en) * 2003-12-05 2005-11-17 The Regents Of The University Of California Office Of Technology Transfer University Of California Peptide inhibitors of HIV
US20060045911A1 (en) * 2004-08-27 2006-03-02 Sun Pharmaceutical Industries Ltd. Stable pharmaceutical formulations
CA2586760A1 (en) * 2004-11-05 2006-05-18 Edward S. Wilson Stabilized ramipril compositions and methods of making
US20070009591A1 (en) * 2005-07-07 2007-01-11 Trivedi Jay S ACE inhibitor formulation
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
EP1948136A1 (de) * 2005-11-07 2008-07-30 King Pharmaceuticals Research and Development, Inc. Zusammensetzungen von stabilisiertem ramipril in kombination mit einem anderen wirkstoff

Also Published As

Publication number Publication date
DE602004019777D1 (de) 2009-04-16
PL1635792T3 (pl) 2009-08-31
CA2530788A1 (en) 2005-01-13
DK1635792T3 (da) 2009-06-15
EP1635792A1 (de) 2006-03-22
WO2005002548A1 (en) 2005-01-13
PT1635792E (pt) 2009-05-15
CA2530788C (en) 2010-02-09
MXPA06000226A (es) 2006-03-21
IL172602A0 (en) 2006-04-10
HK1084015A1 (en) 2006-07-21
US20080058404A1 (en) 2008-03-06
EP1635792B1 (de) 2009-03-04
US20050069586A1 (en) 2005-03-31
US20070212409A1 (en) 2007-09-13
ES2322854T3 (es) 2009-06-30

Similar Documents

Publication Publication Date Title
ATE424192T1 (de) Stabile pharmazeutische zubereitungen mit 2-aza- bicyclo 3.3.0 -octan-3-carboxylsäure-derivaten
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
ES2185179T3 (es) Preparacion de composiciones farmaceuticas.
AP1666A (en) Quinolinone derivatives as tyrosine kinase inhibitors.
ATE359777T1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
ATE391708T1 (de) Verbindungen und gemische zur verabreichung eines aktiven agens
ID26221A (id) Komposisi-komposisi farmasi yang dapat dijadikan gel
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
IL102814A0 (en) Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them
HUP0105173A2 (hu) Adagolási módszer és készítmény sürgősségi fogamzásgátlásra
FI20011703A7 (fi) Jodidia ja jodaattia sisältävä stabiloitu oraalinen farmaseuttinen koostumus sekä menetelmä
BRPI0417938A (pt) formulações de proteìnas hidrofóbicas em uma composição imunogênica que possui tolerabilidade aperfeiçoada
PT1305057E (pt) Composicao de biomateria microparticular para uso medicinal
DE68917937D1 (de) Verbindungen mit magensäureinhibitorwirkung und verfahren zur herstellung.
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
ATE298567T1 (de) Pharmazeutische zusammensetzung enthaltend ibuprofen und ein verfahren zur deren herstellung
ATE301452T1 (de) Verfahren zur herstellung einer flüssigen dosierungseinheit und kit
YU81101A (sh) Polimorfni oblici kristalnog citrata azabiciklo (2,2,2) oktan-3-amina i njihovih farmaceutskih kompozicija
GEP20053581B (en) Pharmaceutical Composition and Method for Preparation Thereof
WO2004014318A3 (en) Levothyroxine compositions and methods
IT1252599B (it) Composizione farmaceutica effervescente anticefalalgica
BR0307451A (pt) Composição pediátrica oral de trimetobenzamida
EA200101157A1 (ru) 14β-H-СТЕРОЛЫ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ЭТИХ ПРОИЗВОДНЫХ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ, РЕГУЛИРУЮЩИХ МЕЙОЗ
RU96111879A (ru) Способ приготовления гомеопатических мягких лекарственных форм
CA2295389A1 (en) Method of treatment of nausea, vomiting, and other disorders using estrogens

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties